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ACMD 
Advisory Council on the Misuse of Drugs 
Chair: Professor Les Iversen 
Secretary: Rachel Fowler  
3rd Floor Seacole Building  
2. Marsham Street  
London  
SW1P 4DF  
020 7035 0454 
Email: ACMD@homeoffice.gsi.gov.uk  
 
            
      
Rt Hon. Theresa May MP  
Home Office 
2 Marsham Street  
London  
SW1P 4DF 
18th October 2012 
 
Dear Home Secretary, 
 
In March 2012 the ACMD advised that methoxetamine be subject to a temporary class drug 
order. Methoxetamine was marketed as a legal alternative to ketamine until a temporary 
class drug order was implemented in April 2012.  As is now required, the ACMD has followed 
its initial assessment with a consideration of methoxetamine in the context of the Misuse of 
Drugs Act 1971; I enclose the report with this letter.  
 
The chemical structure of methoxetamine bears a close resemblance to that of both 
ketamine and phencyclidine (PCP, „Angel Dust‟, a class A drug), which both produce well-
documented and serious adverse effects following both acute and chronic usage. 
 
Users report that the effects of methoxetamine are similar to those of ketamine, however, 
some users report that the effects are of longer duration.The harmful effects reported include 
severe dissociation, cardiovascular symptoms, paranoid thoughts and unpleasant 
hallucinations.   
 
The first analytically confirmed series reported by Guy‟s and St Thomas‟ NHS Foundation 
Trust, London in 2011, was of three individuals who presented having self-reported use of 
methoxetamine. All three presented with a ketamine-like dissociative state, but also had 
significant stimulant effects with agitation and cardiovascular effects including tachycardia 
and hypertension. Toxicological screening of serum samples confirmed methoxetamine use 
in two of the cases. A subsequent analytically confirmed case series has shown that 
methoxetamine also causes significant acute cerebellar toxicity. 
 
The ACMD has reviewed the harms of methoxetamine and finds a broadly similar picture of 
physical harms to that presented in its last report..  
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The ACMD considers, from the available evidence, that the harms of methoxetamine are 
commensurate with Class B, of the Misuse of Drugs Act (1971); and it should be scheduled 
under Schedule I of the Misuse of Drugs Regulations (2001) (having no known recognised 
medicinal use). The ACMD also recommend that a number of closely related analogues of 
ketamine and phencyclidine, some of which have already appeared on sale as „legal high 
alternatives‟, be controlled by means of a generic chemical description detailed in Annex 3. 
 
Yours sincerely,  
 
 
 
Professor Les Iversen  
 
Cc : 
Minister of State for Crime Prevention 
Parliamentary Under Secretary of State for Public Health 
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1. Pharmacology 
 
1.1 Methoxetamine is an analogue of ketamine. Pharmacologically, ketamine‟s main 
action is on glutamate, the major excitatory neurotransmitter in the brain.  It is a non-
competitive antagonist at one of the three glutamate receptor subtypes, the N-methyl 
D-aspartate (NMDA) receptor (Morgan and Curran, 2011). The NMDA receptor is also 
considered to be a key pharmacological target for phencyclidine (Gorelick and Balster, 
1995; Bey and Patel, 2007).  Although there is little information available on the novel 
ketamine and PCP analogues, their behavioural effects in human subjects resemble 
those induced by ketamine and PCP, being characteristic of dissociative anaesthetics 
(Corazza et al, 2012). The wanted effects include euphoria, empathy, dissociation 
from the physical body, hallucinations, but these may be accompanied by adverse 
side effects, which include dizziness, confusion, psychomotor agitation, and cognitive 
impairment. The clinically reported symptoms of acute toxicology of methoxetamine 
include a „dissociative catatonic‟ state similar to that seen with ketamine use, 
accompanied by sympathomimetic toxicity, with significant tachycardia and 
hypertension (Wood et al., 2011; Hofer et al., 2012).  Reversible cerebellar toxicity has 
also been reported in three cases of acute methoxetamine toxicity (Shields et al., 
2012).  A major physical harm associated with chronic ketamine use is bladder and 
renal tract toxicity leading, in particular, to severe ulcerative cystitis which can cause 
bladder dysfunction (Morgan and Curran 2011, Kalsi et al., 2011). Chronic ketamine 
use can also be associated with dependence and a number of other chronic 
complications including abnormal liver function tests, and of neuropsychiatric 
disorders (Kalsi SS 2011). It is not known whether methoxetamine will also prove to 
be associated with these chronic effects. 
 
1.2 The resources of the National Institute of Mental Health “Psychoactive Drug Screening 
Program” were used to obtain neurochemical profiles of methoxetamine and some of 
the novel PCP analogues and to compare these with those of ketamine and PCP and 
other reference compounds. The results confirmed that methoxetamine and the other 
novel analogues have significant affinity for glutamate NMDA receptors, and reveal 
the possibility of other effects mediated by monoamine transporter targets and sigma 
receptors. Interaction with the glutamate NMD receptor is thought to be the key factor 
underlying the mechanism of action of ketamine, phencyclidine and other dissociative 
anaesthetics. 
 
Binding Assays1 
 
1.3 Results of binding assays are given in annex 1.  
 
 
 
                                                 
1 Ki determinations, receptor binding profiles were provided by the National Institute of Mental Health's 
Psychoactive Drug Screening Program (PDSP), Contract # HHSN-271-2008-00025-C (NIMH PDSP). The 
NIMH PDSP is directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and 
Project Officer Jamie Driscol at NIMH, Bethesda MD, USA. 
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2. Chemistry 
 
2.1 Methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone) is one of a group 
of compounds collectively referred to as the arylcyclohexylamines. Other compounds 
of this type have applications as anaesthetics and some have been used as 
recreational drugs. Perhaps the best known arylcyclohexylamines are phencyclidine 
(1-(1-phenylcyclohexyl)piperidine, „PCP‟, „Angel dust‟) and ketamine (2-(2-
chlorophenyl)-2-(methylamino)cyclohexanone, „Special K‟).   
 
 
 
 
 
 
 
 
 
2.2 PCP and some related materials (Eticyclidine, Rolicyclidine, Tenocyclidine) are 
controlled as Class A drugs (see Annex 2 for structures).  
 
2.3 Synthesis of methoxetamine is achievable by 4 steps through simple reactions 
involving an aromatic nitrile, a Grignard reagent, bromination, imine formation through 
reaction with a suitable amine, followed by the application of heat to the product to 
allow ring expansion (Hays et al., 2012). This process is presumably readily applicable 
to analogues of methoxetamine by substitution of starting aromatic nitrile and selected 
amine to afford the desired N-substituted derivative analogues of methoxetamine. 
 
2.4 Ketamine, a human and veterinary pharmaceutical which became popular as a 
recreational drug,  was made a Class C drug in 2005. Methoxetamine was 
subsequently advertised, by legal high suppliers, as a legal alternative to ketamine, 
that is, as a „designer drug‟.  
 
2.4     „Legal high‟ websites are currently offering other novel uncontrolled psychoactive 
substances -  arylcyclohexylamines - including 3-methoxy and 4-methoxy PCP, and 
these were also found to interact with high affinity at the NMDA receptor (see Annex 
2). 
 
2.5 2-Methoxy ketamine, another arylcyclohexylamine (table 2) closely related to 
methoxetamine and ketamine, has recently been announced by several websites as a 
new product and on 30th August 2012 the EMCDDA reported that the Swedish Police 
had made the first seizure of this variant of ketamine in Europe. 
 
2.6     In early September 2012, a further new compound of this type, N-ethyl-nor-ketamine 
(„NEK‟, Annex 2) was made available on a number of websites. Its identity was 
confirmed by an EMCDDA notification issued on 17th September, 2012. This material 
is a homologue of ketamine, that is, it has a chemical structure identical to ketamine, 
except that the N-methyl group is replaced by an N-ethyl group, so the compound can 
be expected to have effects that are substantially similar to those of ketamine. 
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3. Harms  
 
Acute Harm 
3.1 There have been six published cases of analytically confirmed acute methoxetamine 
toxicity presenting to hospitals in the UK (Wood, 2012, Shields, 2012). In addition to 
the analytically confirmed cases from London and York, there is anecdotal information 
on presentations to hospitals in other areas of the UK including Scotland, the Midlands 
and the South West.  
 
3.2 Analysis of NPIS data collected up to the end of July 2012 demonstrates that there 
have been 47 telephone enquiries to the UK National Poisons Information Service 
(NPIS) concerning cases of suspected methoxetamine exposure or toxicity; the first of 
these was in October 2010. In addition there have been 298 user sessions to the 
monograph for methoxetamine on TOXBASE, the online poisons information database 
for the NPIS from the date of its publication in May 2011 until 31st July 2012.  
  
3.3 The most common clinical features reported in telephone enquiries to NPIS following 
methoxetamine exposure were agitation and tachycardia. Hypertension, confusion, 
dizziness, euphoria, somnolence, catatonia or hypertonia and elevated creatine kinase 
were also documented commonly (>8% cases). 
  
3.4 Data from NPIS needs to be interpreted with caution as the National Poisons 
Information Service usage can only give surrogate information on presentations to 
hospital with toxicity and case numbers are limited. However these data suggest 
increasing presentations to hospitals related to the use of methoxetamine, particularly 
since November 2011. Telephone enquiry and TOXBASE session numbers have 
fallen since April 2012, suggesting a possible association with the temporary class 
order on the availability and prevalence of use of methoxetamine that came into effect 
on 5th April 2012. 
 
3.5 The first analytically confirmed series reported by Guy‟s and St Thomas‟ NHS 
Foundation Trust, London in 2011, was of 3 individuals who presented having used 
methoxetamine. All three presented with a ketamine-like dissociative state but also 
had significant cardiovascular stimulant effects: tachycardia (113–135 bpm) and 
hypertension (systolic BP 187–201 mm Hg, diastolic BP 78-104mmHg). Toxicological 
screening of serum samples confirmed methoxetamine use (serum methoxetamine 
concentrations 0.09–0.2 mg/L) and this was the only detected substance in 2 of the 
cases (Wood, 2012). 
 
3.6 The second analytically confirmed series was of 3 individuals in York who presented 
with mild stimulant cardiovascular features (HR 67–107 bpm, systolic BP 148–194 
mmHg, diastolic BP 104–112 mm Hg). In addition all of them had significant cerebellar 
signs (truncal ataxia [unsteadiness on their feet], nystagmus and incoordination) that 
persisted for up to 3-4 days. Toxicological screening of serum samples confirmed 
methoxetamine use (0.24-0.45 mg/L), and no other drugs were identified on an 
extended toxicological screen (Shield, 2012). 
 
3.7 In summary, methoxetamine appears to be associated with some features that are 
similar to ketamine (hallucinations, drowsiness, and dissociative effects). Ketamine 
can cause mild hypertension, however the hypertension reported in methoxetamine 
toxicity is greater than what would generally be expected with ketamine toxicity. In 
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addition to more significant hypertension, methoxetamine appears to be associated 
with additional toxicity compared to ketamine including agitation, other stimulant 
effects such as tachycardia (a fast heart rate) and cerebellar features. Cerebellar 
features such as ataxia (unsteadiness on the feet), are rarely seen with other 
recreational drugs and are not seen with acute ketamine toxicity.  
 
Chronic Harm 
3.8 Regular use of ketamine is associated with a range of chronic problems including 
bladder and other lower urinary tract pathology (Kalsi SS et al.,  2011). 
 
3.9 Methoxetamine is frequently marketed as “bladder friendly”, however preliminary data 
from animal studies show that it is associated with significant bladder and kidney 
toxicity (Wood DM et al., Clin Toxicol (Phila) 2012). There is currently no data to 
determine how this compares to the effects seen with ketamine in the same animal 
models. 
 
3.10 There are currently no reported human cases of methoxetamine related bladder 
toxicity, however it has only been available / used for 1-2 years and therefore it is 
possible that it is too early for these effects to have been reported.  
 
3.11 Regular use of ketamine is also associated with other chronic toxicity including gall 
bladder, gastrointestinal and central nervous system damage. There is currently no 
published animal or human data to determine whether methoxetamine has similar 
effects.  
 
Deaths 
3.12 The ACMD is not aware of any deaths solely attributed to methoxetamine.   
 
Crime  
3.13 Methoxetamine was openly offered for sale on UK websites prior to the temporary 
ban. Implementation of the ban had a real and immediate impact in tackling internet 
sales of methoxetamine with a significant proportion of UK websites ceasing to 
advertise its sale.  It is possible that methoxetamine remains available online but sold 
under other descriptions.  However, the extent of such availability and of 
methoxetamine's prevalence in the market place is unclear. Since the temporary ban, 
seizures of Methoxetamine in the Metropolis have been low, spread over a broad area 
with no obvious hot spots.  It does not seem to be a drug of choice; it is not particularly 
prevalent and is not a crime generator. 
  
International data 
3.14   The ACMD are not aware of any confirmed deaths solely related to methoxetamine 
reported in Europe or elsewhere in the world.  
 
3.15    There has been one published case of potential acute methoxetamine toxicity from 
Switzerland and one from the USA. These cases are summarised below.  
 
3.16    The US case was an individual who presented to the Emergency Department after 
self-reported methoxetamine use in a dissociative state. In addition he had mild 
stimulant features (HR 105 bpm, BP 140/95 mm Hg) and bilateral nystagmus 
(abnormal eye movements). Analysis of a drug specimen suggested that the drug 
used was methoxetamine, however it is not possible to determine definitively whether 
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toxicity was due to methoxetamine as there was no toxicological screening of 
biological samples to confirm actual use of methoxetamine (Ward J 2011). 
 
3.17   The case from Switzerland was an individual who reported injection of methoxetamine. 
On arrival in the Emergency Department, he was agitated, had ataxia, and was 
disoriented. He also had stimulant features (HR 134 bpm, BP 168/77 mm Hg) and a 
mild pyrexia (37.6°C). However, this individual had also injected MDMA (3,4-
methylenedioxymethamphetamine) 2 days previously. Analysis of serum samples 
taken 5 hours after injection of methoxetamine showed both methoxetamine and 
MDMA and therefore it is not possible to determine the relative role of these drugs in 
the presentation (Hofer KE 2012).  
 
3.18    In addition there are anecdotal reports of acute methoxetamine toxicity presentations 
to hospitals in other countries in Europe including in Belgium.  
 
Treatment services 
3.19 FRANK and Know the Score provide general information about methoxetamine and its 
current legal status. Information provided focuses on dissociative effects of 
methoxetamine, and both sites list some adverse effects that it is claimed are not seen 
with ketamine (involuntary eye movement, loss of balance and poor coordination, gait 
instability and slurred speech). However, it is unclear what the source of this claim is. 
The two sites also suggests that methoxetamine is/was being marketed as a „bladder 
safe‟ replacement for ketamine, but again, the source of this statement, and relevance 
in light of the temporary class drug order (TCDO), is uncertain. As ketamine is injected 
by some users (it is unknown whether this is also true for methoxetamine), general 
information is provided on the risks of methoxetamine injection, and how sharing of 
equipment may lead to increased risk of transmission of blood borne viruses. DAN 
(Wales) does not currently provide any methoxetamine information on its website. 
 
3.20 Several other internet sites provide information on methoxetamine, that upon initial 
inspection seem reliable. For example, the Vaults of Erowid methoxetamine pages 
provide a more comprehensive overview than FRANK, with the inclusion of links to 
some scientific studies and user reports. The Independent Scientific Committee on 
Drugs includes similar information to FRANK but also provides general harm reduction 
advice. Crew 2000 (www.crew2000.org.uk; a drug service based in Edinburgh) have 
published a methoxetamine briefing targeted at users and drug workers which 
includes information on dose and user patterns, harm reduction, and weblinks. 
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4. Prevalence of use and price  
 
4.1 There is only a small amount of evidence of methoxetamine use in the UK, and this is 
largely confined to nightlife populations; this does not, however, mean that the 
prevalence of use is low. As methoxetamine is not included in the Crime Survey for 
England and Wales (CSEW; formerly British Crime Survey) it is unclear to what extent 
methoxetamine had dispersed amongst the general population and whether 
geographic variations in use exist. There is currently no evidence available on user 
typology and so it is not possible to predict which groups are most likely to use 
methoxetamine. Surveys have been conducted which have indicated some use 
amongst gay male „clubbers‟ and young adult „clubbers‟ and music festival attendees. 
However, this is because these populations have been specifically targeted for 
research. 
 
4.2 There are three small prevalence studies to date, and to the best of ACMD‟s 
knowledge no other studies are in preparation. The prevalence data reported below is 
largely the same as reported in the ACMD‟s earlier report on methoxetamine which 
was prepared in order to inform the temporary class drug order recommendation and 
therefore figures do not reflect the apparent reduction in availability of methoxetamine. 
In the absence of robust epidemiological data it is unknown if the introduction of the 
TCDO affected methoxetamine prevalence.  
 
4.3 It is not possible to provide a UK estimate of methoxetamine prevalence. For 
comparison purposes, ketamine was reportedly used by 0.6% of the adult population 
(16-59 years old) in the previous year (2011/12 CSEW data); 1.8% of 16-24 year olds 
reported use in the same reporting period, a decrease from 2.1% in 2010/11. 
 
4.4 A survey has been conducted across four nights in two South London gay dance clubs 
in July 2011, 6.4% of respondents (82% men, mean age 29.7) reported lifetime use of 
methoxetamine, 1.9% in the previous month, and 1.6% on the night of survey (Wood 
et al, 2012). For comparison, 76% reported a lifetime use of cocaine, 69 % ecstasy 
and 64% mephedrone. The lifetime prevalence of other „Novel Psychoactive 
Substances‟ (NPS) was low (e.g. MDAI 7.7%), which led the authors to conclude that 
of these category of drugs, only mephedrone has become established in nightlife. 
  
4.5 A survey by Welch and colleagues (2012) undertaken in Lancashire nightclubs in 
March 2012 found low levels of methoxetamine use. Customers at these nightclubs 
would be expected to be more representative of the general public than those 
frequenting dance clubs, given that these were „mainstream‟ nightclubs that were 
selected at random from all late licensed dancing venues in the fieldwork area. Whilst 
no-one reported either having already taken or planning to take methoxetamine on the 
fieldwork night, 3.6% reported having tried it at least once in their lifetime, 2.6% within 
the last year (March 2011-12) and 1.9% within the last month. 
 
4.6 An online survey of self-selected and self-reported substance use conducted 
November 2011 (Global Drug Survey2) found, of the 7,700 respondents in the UK, 
4.2% reported using methoxetamine in the previous year (6% of clubbers and 4% of 
non clubbers) and 2.4% reported using methoxetamine in the previous month (3% of 
                                                 
2
 Data available from 
https://docs.google.com/spreadsheet/ccc?key=0AonYZs4MzlZbdDdrY2NMeWZpQzZwekxUU19TdWVrc3c#gid
=0 
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clubbers and 1% of non clubbers). Self reported methoxetamine use amongst this 
group was higher than the use of a range of other drugs including: DMT; synthetic 
cannabinoids; Benzofury; MDAI; crack; GBL; BZP; heroin etc. 
 
4.7 The same survey reported that 14.4% of last year methoxetamine users would like to 
use less methoxetamine, and 1% would like to stop. The reasons for 
reduction/cessation weren‟t provided.  
 
4.8 Anecdotal evidence obtained from drug user forums suggests that some users 
combine methoxetamine with other compounds, including some tryptamine and 
phenethylamine derivatives (Corazza et al., 2012), although the veracity of this 
information is uncertain. 
 
4.9 Recent studies conducted in the Westminster and Soho area of central London have 
detected methoxetamine in urinals indicating that it is being used amongst individuals 
frequenting the night time economy in these areas (Archer J et al., 2012) 
 
Police exercise to measure prevalence of methoxetamine 
4.10 The ACMD notes that Avon and Somerset Constabulary undertook an exercise to 
measure the prevalence of methoxetamine across England and Wales from a policing 
perspective. The following actions undertaken;   
 
 All Police Forces in England and Wales were contacted for their methoxetamine 
seizure data over the last 12 months (it is noted that the TCDO only came into 
force in April 2012). 
 The three main Forensic providers contacted for their methoxetamine seizure data 
for 2012. 
 
4.11 In total 36 replies from Police Forces in England and Wales were received, of these, 
14 Forces state that they had made a total of 49 seizures of methoxetamine. 29 of 
these seizures occurred in the South of England (Kent to the South West) and the rest 
evenly spread across the Midlands, North England and Wales.It is noted that even 
when a drug is identified by their Forensic provider many Police Forces do not list that 
drug in their returns unless it has a Home Office code - this may explain the disparity 
between Police and Forensic providers figures below. 
 
4.12 The number of methoxetamine seizures supplied to the Forensic providers by Police 
during 2012 was: 
 
 ESG (Environmental Scientific Group) – 75 
 LGC (LGC Forensics) – 171 
 KEY (Key Forensic Services Limited) – 3 
4.13 In June 2012 Police reports to the ACMD indicated  that methoxetamine was not 
considered prevalent in any Police Force in England and Wales. Some of the Forces 
that were seizing the drug stated that many of their seizures were as a result of action 
against “Legal High shops”.  That view does not appear to have changed. 
 
 
 
Methoxetamine price 
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4.14 Before being subject to a TCDO, and dependent upon the retailer, methoxetamine 
was available for purchase online for around £5-10 for 250mg, and >£3500 for 1kg 
(manufacturer prices unknown). As of 30/8/12 five purported UK based sellers were 
offering methoxetamine for sale on the Silk Road website (an „anonymous‟ 
marketplace accessed using the Tor „hidden service‟ browser). Prices ranged from 
1.82 Bitcoins (1 Bitcoin [฿] ~£7 at the time of writing) for 500mg to 104.24 ฿ for 50g. 
Sellers purportedly based in China and the USA were offering the opportunity to 
purchase 1kg of methoxetamine for around 500 ฿. This indicates a trade outside of 
those normal routes of access and purchase. According to some drug services street 
prices are currently around £15-20/g. 
 
Methoxetamine identified by FEWS at Music Festivals across the UK in 2012 
 
4.15 In the summer of 2012, the Home Office Forensic Early Warning System (FEWS) 
installed and ran on-site drugs laboratories at six music festivals across the UK. The 
aim of this was to (i) provide intelligence data to the Police regarding the drugs being 
encountered at the festivals and (ii) to gather information on new psychoactive 
substances (NPS) for FEWS.  Packets and wraps containing a range of powders, 
capsules and herbal products were collected from drug amnesty bins, police arrests 
and welfare tents.  
 
4.16 All the samples were tested using either colorimetric and immunoassay kits and then 
analysed by Gas Chromatography – Mass Spectrometry (GC-MS). The identifications 
were based on MS library matches together with GC retention times in some cases. 
Methoxetamine was encountered in both tablet and powder form in 20 of the 1091 
samples which were analysed.  It was a single component in some samples and found 
in combination with other drugs which are controlled under the Misuse of Drugs Act, 
1971; uncontrolled NPS and cutting agents.  
 
 Six powder samples were identified as methoxetamine only. 
 Five powder samples were mixtures in which methoxetamine was combined with  
i. mephedrone; 
ii. lidocaine, 4-methyl buphedrone, caffeine, 5-MeO-DALT, cocaine and MDAI;  
iii. TFMPP, caffeine, MDAI, cocaine and 5-MeO-DALT; 
iv. 5-MeO-DALT, methylone and 5/6-APB and  
v. 5-MeO-DALT, methylone, 5/6-APB and 2-DPMP. 
 At three of the festivals, methoxetamine was identified nine times in tablets which also 
contained   
i. MDMA, n-ethylbuphedrone, 4-MEC and caffeine.  
All the samples containing methoxetamine were either in clear poly-bags or wraps and 
were never seen in a branded product.  
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5. Conclusions and Recommendatios  
 
5.1 The ACMD notes that although the number of seizures nationally is relatively low at 
approximately 270 in 2012 so far, it is clear that methoxetamine is a popular drug 
especially amongst ketamine users. Notwithstanding the low seizure figures it would 
appear to be available across the whole of England and Wales, considering its 
Temporary Class Drug status, methoxetamine has been found in “Legal High” 
samples seized by Police. There is also evidence that suggests that users refer to 
methoxetamine as the “bladder safe” ketamine which, with ketamine‟s increasing 
popularity in mind, may lead to an increase in the use of methoxetamine. 
 
5.2      Methoxetamine appears to be associated with some features that are similar to 
ketamine (hallucinations, drowsiness, and dissociative effects). The hypertension 
reported in methoxetamine toxicity is greater than what would generally be expected 
with ketamine toxicity. In addition to more significant hypertension, methoxetamine 
appears to be associated with additional toxicity compared to ketamine including 
agitation, other stimulant effects such as tachycardia (a fast heart rate) and cerebellar 
features. Cerebellar features such as ataxia (unsteadiness on the feet), are rarely 
seen with other recreational drugs and are not seen with acute ketamine toxicity.  
 
5.3    Regular use of ketamine is associated with a range of chronic problems including 
chronic bladder and other lower urinary tract pathology. Methoxetamine is frequently 
marketed as “bladder friendly”, however preliminary data from animal studies show 
that it is associated with significant bladder and kidney toxicity (Wood, 2012). 
 
5.4      It is recommended that the harms of methoxetamine and the various other analogues 
of ketamine and phencyclidine, described in 5.2 and 5.3 above (compounds described 
in the generic scope), are commensurate with other Class B compounds. Therefore 
the ACMD recommends that methoxetamine and compounds in the generic scope 
below be brought under the Misuse of Drugs Act 1971 as Class B compounds and be 
placed in Schedule 1 of the Misuse of Drugs Regulations (2001) as amended.  
 
5.5.    The ACMD, in its report „consideration of the Novel Psychoactive (‘legal highs’) „ 
provided a number of cross-cutting recommendations in relation to public health, 
treatments and availability.  The ACMD believes that these recommendations are 
relevant to methoxetamine, and should be re-visited by the relevant Departments in 
order to consider harm reductions measures in relation to methoxetamine.   
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Annex 1. Results of binding assays of methoxetamine 
 
Compounds were initially screened in quadruplicate primary assays at a fixed concentration 
of 10µM. Those which yielded inhibition of tracer binding of more than 50% at this 
concentration were subjected to Secondary assays in which test substance concentrations 
ranging from 10pM to 10µM were tested in triplicate to yield concentration effect curves from 
which pKi and Ki values were calculated. For experimental details refer to the PDSP web site 
http://pdsp.med.unc.edu/ and click on "Binding Assay" or "Functional Assay" on the menu 
bar. All compounds were screened against the targets listed in Table 1 below.  
 
Table 1: Primary and Secondary Radioligand Binding Assays 
Serotonin Receptors 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C,               
5-HT6, 5-HT7 
Dopamine Receptors D1, D2, D3, D4 
Glutamate Receptors NMDA Receptor (MK-801 binding site), mGluR5 
GABA Receptors GABA-A, GABA-B 
Biogenic Amine 
Transporters 
SERT, NET, DAT 
Adrenoceptors α 2A, α 2B, α 2C. β 1 
Muscarinic Receptors M1, M2, M3, M4 
Opioid Receptors MOR, KOR, DOR 
Sigma Receptors Sigma1, Sigma2 
Histamine Receptors H1, H2 
 
Results 
Table 2 summarises the results obtained with compounds that were active in the Primary 
assays at 10µM,  
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Table 2: Results of Binding assays – pKi ± SE, (Ki) nM 
Open boxes with – indicate that compounds failed the Primary Screen criterion of >50% 
inhibition at 10µM. All the compounds failed the Primary Screen criterion in the other 
screening targets listed in Table 1. 
 
Compound NMDA SERT NET Sigma1 Sigma2 
Ketamine 6.18±0.07 
(659) 
- - - - 
Phencyclidine  
7.23±0.07 
(59) 
5.65±0.05 
(2234) 
- - 6.82±0.09 
(136) 
Methoxetamine 6.59±0.06 
(259) 
6.32±0.05 
(481) 
- - - 
4-MeO-PCP 6.39±0.06 
(404) 
6.07±0.05 
(844) 
6.1±0.1 
(713) 
6.5±0.1 
(296) 
7.93±0.08 
(143) 
3-MeO-PCP  
7.69±0.08 
(20) 
6.7±0.1 
(216) 
- 7.4±0.1 
(42) 
- 
 
NMDA (N-methyl-D-aspartate receptor); SERT (serotonin transporter); NET 
(norepinephrine transporter) 
 
Conclusions from binding data 
 
The results obtained in receptor screening confirm that the novel analogues share the profile 
of ketamine and PCP as ligands for the glutamate NMDA receptor. The binding data 
revealed methoxetamine to have an affinity for the NMDA receptor comparable to or higher 
than the parent compound ketamine. The methoxy analogues of PCP also had appreciable 
affinities for the NMDA receptor, and 3-MeO-PCP in particular proved particularly active, with 
a Ki of 20 nM placing it among the most potent known NMDA antagonists (cf dizocilpine (MK-
801) Ki = 4.8nM). 
 
Methoxetamine and the phencyclidine analogues also had appreciable affinity for the 
serotonin transporter (SERT) (Table 2). The affinity of methoxetamine for SERT was similar 
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to its affinity for the NMDA receptor, suggesting that inhibition of SERT and a resulting 
increase in the release of serotonin in the brain may contribute to its psychopharmacological 
profile and the additional features seen in acute methoxetamine toxicity. 
16 
 
Annex 2. Structure of methoxetamine and closely related compounds – see Annex 4 
for those compounds that would be captured by the proposed generic definition 
(generic description provided at Annex 3). 
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Annex 3. Proposed generic definition. 
 
Generic definition of the arylcyclohexylamine dissociative anaesthetics.  
 
 
1-Phenylcyclohexylamine or any compound (not being ketamine, tiletamine or a compound 
for the time being specified in paragraph (a) of schedule 1 above) structurally derived from 1-
phenylcyclohexylamine or 2-amino-2-phenylcyclohexanone by modification in any of the 
following ways, that is to say, 
 
(i) by substitution at the nitrogen atom to any extent with alkyl, alkenyl or hydroxyalkyl 
groups, or replacement of the amino group with a 1-piperidyl, 1-pyrrolidyl or 1-azepyl 
group whether or not the nitrogen containing ring is further substituted with one or 
more alkyl groups; 
 (ii) by substitution in the phenyl ring to any extent with amino, alkyl, hydroxy, alkoxy or 
halide substituents, whether or not further substituted in the phenyl ring to any extent; 
(iii) by substitution in the cyclohexyl or cyclohexanone ring with one or more alkyl 
substituents; 
(iv) by replacement of the phenyl ring with a 2-thienyl ring.  
 
[Note: If Class B is preferred then Schedule 2, Part II, paragraph 2A would need amending ie 
provisions for esters and ethers since the above generic definition covers those compounds 
that include an –OH functional group on the phenyl ring]. 
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Annex 4. Examples of compounds that would be controlled by the proposed generic 
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